Roche Accutane Exhibit Hall Response On Psychosis Risk Draws FDA Letter
Executive Summary
Roche's response to a question about Accutane-associated psychosis asked at the company's exhibit booth during the American Pharmaceutical Association annual meeting minimizes the drug's risk of psychiatric disorders, an FDA ad division letter says
You may also be interested in...
Amnesteem Cannot Claim “Esteem,” FDA Tells Mylan In Letter On Acne Drug
FDA is citing Mylan for claims on Amesteem's website that the acne product can address problems with low self-esteem
Amnesteem Cannot Claim “Esteem,” FDA Tells Mylan In Letter On Acne Drug
FDA is citing Mylan for claims on Amesteem's website that the acne product can address problems with low self-esteem
CDER Ombudsman Warren Rumble Inherits Increasing Complaints
One of the issues facing CDER Acting Ombudsman Warren Rumble is a rise in internal complaints at the drug center